AstraZeneca PLC (AZNCF)
Market Cap | 223.00B |
Revenue (ttm) | 54.98B |
Net Income (ttm) | 7.77B |
Shares Out | n/a |
EPS (ttm) | 4.97 |
PE Ratio | 28.69 |
Forward PE | 15.46 |
Dividend | 3.10 (2.18%) |
Ex-Dividend Date | Feb 20, 2025 |
Volume | 1,200 |
Average Volume | 1,752 |
Open | 145.02 |
Previous Close | 142.48 |
Day's Range | 145.02 - 147.08 |
52-Week Range | 120.64 - 175.00 |
Beta | 0.17 |
RSI | 54.29 |
Earnings Date | Jul 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, ...

AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, ...
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes ...
ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial
Daiichi Sankyo and AstraZeneca's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes ...
Experimental AstraZeneca pill helps cut risk of breast cancer progression
CNBC's Joe Kernen reports on the latest news.

Experimental AstraZeneca pill helps cut risk of breast cancer progression
CNBC's Joe Kernen reports on the latest news.
Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca's DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC TROPION-...

'Transformational' new drug could stop breast cancer tumours before they grow, trial finds
A new drug could stop some breast cancer tumours from using hormones to grow, a trial has found.

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding...

AstraZeneca unveils drug to treat mutating breast cancer before it starts to grow
Pharma group estimates Camizestrant could be worth up to $5bn of sales in its peak year

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbocic...
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial
Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting Positive results from the DESTINY-G...
Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid...
Looking Into AstraZeneca's Recent Short Interest
AstraZeneca's (NYSE: AZN) short percent of float has risen 50.0% since its last report. The company recently reported that it has 7.34 million shares sold short , which is 0.24% of all regular shares...
AstraZeneca wins EU backing for Imfinzi in bladder cancer
Why AstraZeneca May Be 2025's Most Underrated Pharma Stock

Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and AstraZeneca announce licensing agreement to develop AI-powered screening algorithms for early disease detection.
AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
SERENA-6 plenary presentation will feature next-generation oral SERD camizestrant in 1st-line advanced HR-positive breast cancer MATTERHORN plenary presentation will showcase perioperative treatment w...

AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American S...